Barbara Hebeis

Title: Barbara Hebeis: Innovator in Antibody Molecules

Introduction

Barbara Hebeis is a prominent inventor based in Cambridge, GB. She has made significant contributions to the field of biotechnology, particularly in the development of antibody molecules that target specific proteins involved in cancer therapy.

Latest Patents

Barbara holds a patent for her invention titled "Binding molecules binding PD-L1 and LAG-3." This invention relates to antibody molecules that bind to programmed death-ligand 1 (PD-L1) and lymphocyte-activation gene 3 (LAG-3). The antibody molecules are designed to include a CDR-based antigen binding site for PD-L1, along with a LAG-3 antigen binding site that may be located in two or more structural loops of a CH3 domain of the antibody molecule. The applications of these antibody molecules are particularly relevant in the field of cancer therapy.

Career Highlights

Throughout her career, Barbara has worked with notable companies in the biotechnology sector, including F-star Therapeutics, Inc. and F-star Delta Limited. Her work has been instrumental in advancing therapeutic strategies that leverage the immune system to combat cancer.

Collaborations

Barbara has collaborated with esteemed colleagues such as Jamie Iain Campbell and Nikole Sandy, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Barbara Hebeis is a trailblazer in the field of antibody research, with her innovative patent paving the way for new cancer therapies. Her contributions continue to impact the biotechnology landscape significantly.